These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33946783)

  • 21. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
    Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
    Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SHetA2 Dry Powder Aerosols for Tuberculosis: Formulation, Design, and Optimization Using Quality by Design.
    Ibrahim M; Hatipoglu MK; Garcia-Contreras L
    Mol Pharm; 2018 Jan; 15(1):300-313. PubMed ID: 29219321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation.
    Moon C; Watts AB; Lu X; Su Y; Williams RO
    Mol Pharm; 2019 May; 16(5):1799-1812. PubMed ID: 30925839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO; Elsayed MMA
    AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical equivalence of the combination formulation of budesonide and formoterol in a single capsule with a dry powder inhaler.
    Andrade-Lima M; Pereira LF; Fernandes AL
    J Bras Pneumol; 2012; 38(6):748-56. PubMed ID: 23288120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel dry powder inhaler formulation containing antibiotic using combined technology to improve aerodynamic properties.
    Ambrus R; Benke E; Farkas Á; Balásházy I; Szabó-Révész P
    Eur J Pharm Sci; 2018 Oct; 123():20-27. PubMed ID: 30016647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability test of novel combined formulated dry powder inhalation system containing antibiotic: physical characterization and
    Benke E; Farkas Á; Balásházy I; Szabó-Révész P; Ambrus R
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1369-1378. PubMed ID: 31096805
    [No Abstract]   [Full Text] [Related]  

  • 30. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
    Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
    Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supercritical Fluid Particle Design of DPI Formulations (Review).
    Sun Y
    Curr Pharm Des; 2015; 21(19):2516-42. PubMed ID: 25876911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF; Ferrati S; Moraga-Espinoza DF; Smyth HDC
    J Pharm Sci; 2018 Aug; 107(8):2172-2178. PubMed ID: 29698726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation development and in vivo evaluation of a new dry powder formulation of albuterol sulphate in beagle dogs.
    Kuehl PJ; Barrett EG; McDonald JD; Rudolph K; Vodak D; Dobry D; Lyon D
    Pharm Res; 2010 May; 27(5):894-904. PubMed ID: 20232119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
    Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
    Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis.
    Zhang Y; MacKenzie B; Koleng JJ; Maier E; Warnken ZN; Williams RO
    Mol Pharm; 2020 Feb; 17(2):632-644. PubMed ID: 31913640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
    You Y; Zhao M; Liu G; Tang X
    J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
    Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
    Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
    Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.